Tags

Type your tag names separated by a space and hit enter

Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study.
Pharmacopsychiatry. 1989 Jan; 22(1):38-41.P

Abstract

Savoxepine is a new tetracyclic compound displaying potent neurolepticlike effects in pharmacological studies. Of particular interest is its preferential binding to dopamine-2 receptors in the hippocampus, which leads to the hypothesis that savoxepine may exert antipsychotic effects at doses not inducing extrapyramidal side-effects. In an open pilot-study 18 patients suffering from acute schizophrenic psychoses or paranoid syndromes were treated with savoxepine in an individually adapted dose range from 0.50 to 10 mg per day. A good antipsychotic efficacy could be demonstrated in 10 of 16 patients. Savoxepine was found to be generally well tolerated. Contrary to expectations, mild or moderate extrapyramidal side-effects, especially of the parkinsonian type, were registered. Future research has to test the suggested advantage of savoxepine in comparison with other neuroleptic drugs.

Authors+Show Affiliations

Department of Psychiatry, Technical University, Munich, FRG.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2565583

Citation

Möller, H J., et al. "Efficacy and Tolerability of a New Antipsychotic Compound (savoxepine): Results of a Pilot-study." Pharmacopsychiatry, vol. 22, no. 1, 1989, pp. 38-41.
Möller HJ, Kissling W, Dietzfelbinger T, et al. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry. 1989;22(1):38-41.
Möller, H. J., Kissling, W., Dietzfelbinger, T., Stoll, K. D., & Wendt, G. (1989). Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry, 22(1), 38-41.
Möller HJ, et al. Efficacy and Tolerability of a New Antipsychotic Compound (savoxepine): Results of a Pilot-study. Pharmacopsychiatry. 1989;22(1):38-41. PubMed PMID: 2565583.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. AU - Möller,H J, AU - Kissling,W, AU - Dietzfelbinger,T, AU - Stoll,K D, AU - Wendt,G, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 38 EP - 41 JF - Pharmacopsychiatry JO - Pharmacopsychiatry VL - 22 IS - 1 N2 - Savoxepine is a new tetracyclic compound displaying potent neurolepticlike effects in pharmacological studies. Of particular interest is its preferential binding to dopamine-2 receptors in the hippocampus, which leads to the hypothesis that savoxepine may exert antipsychotic effects at doses not inducing extrapyramidal side-effects. In an open pilot-study 18 patients suffering from acute schizophrenic psychoses or paranoid syndromes were treated with savoxepine in an individually adapted dose range from 0.50 to 10 mg per day. A good antipsychotic efficacy could be demonstrated in 10 of 16 patients. Savoxepine was found to be generally well tolerated. Contrary to expectations, mild or moderate extrapyramidal side-effects, especially of the parkinsonian type, were registered. Future research has to test the suggested advantage of savoxepine in comparison with other neuroleptic drugs. SN - 0176-3679 UR - https://www.unboundmedicine.com/medline/citation/2565583/Efficacy_and_tolerability_of_a_new_antipsychotic_compound__savoxepine_:_results_of_a_pilot_study_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-1014575 DB - PRIME DP - Unbound Medicine ER -